Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Akr1d1-/-mice have a sexually dimorphic metabolic phenotype with reduced fat mass, increased insulin sensitivity and hypertriglyceridemia in males

Gathercole LL. et al, (2021), bioRxiv, 2021.02.02.429227 - 2021.02.02.429227

Differential activity and expression of human 5β-reductase (AKR1D1) splice variants

Appanna N. et al, (2021), Journal of Molecular Endocrinology

The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies

NIKOLAOU N. et al, (2021), The Journal of Steroid Biochemistry and Molecular Biology, 105808 - 105808

The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1

Barnard L. et al, (2020), The Journal of Steroid Biochemistry and Molecular Biology, 105724 - 105724

Co-administration of 5α-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids

Othonos N. et al, (2020), The Journal of Clinical Endocrinology & Metabolism

Differential activity and expression of human 5β-reductase (AKR1D1) splice variants

Appanna N. et al, (2020), bioRxiv

Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo.

Nikolaou N. et al, (2020), J Endocrinol

5[beta]-reductase (AKR1D1) isoforms differentially regulate natural and synthetic glucocorticoid clearance and glucocorticoid receptor activation in vitro

Appanna N. et al, (2019), Endocrine Abstracts

5[beta]-reductase (AKR1D1) is downregulated in patients with non-alcoholic fatty liver disease and protects against hepatocellular carcinoma cell proliferation in vitro

Nikolaou N. et al, (2019), Endocrine Abstracts

AKR1D1 (5[beta]-reductase) deletion drives hepatic inflammation, fibrosis and tumour development in vivo

Harris S. et al, (2019), Endocrine Abstracts

Intestinal injury and evidence of increased gut permeability in female AKR1D1 knockout mice

Arvaniti A. et al, (2019), Endocrine Abstracts

AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease

Nikolaou N. et al, (2019), Metabolism, 153947 - 153947

AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells.

Nikolaou N. et al, (2019), J Steroid Biochem Mol Biol, 189, 218 - 227

Differential regulation of 5[beta]-reductase (AKR1D1) expression and activity by glucocorticoids in human and rodent liver

Nikolaou N. et al, (2019), Endocrine Abstracts

5β-reductase (AKR1D1) is a potent regulator of hepatic insulin sensitivity, carbohydrate and lipid metabolism in vitro and in vivo

Nikolaou N. et al, (2018), Endocrine Abstracts, 59

5[beta]-reductase (AKR1D1) is a potent regulator of hepatic insulin sensitivity, carbohydrate and lipid metabolism in vitro and in vivo

Nikolaou N. et al, (2018), Endocrine Abstracts

Male AKR1D1 (5[beta]-reductase) knockout mice have altered pancreatic islet morphology and hormone secretion

Harris S. et al, (2018), Endocrine Abstracts

Modified-Release and Conventional Glucocorticoids and Diurnal Androgen Excretion in Congenital Adrenal Hyperplasia.

Jones CM. et al, (2017), J Clin Endocrinol Metab, 102, 1797 - 1806

Optimizing human hepatocyte models for metabolic phenotype and function: effects of treatment with dimethyl sulfoxide (DMSO).

Nikolaou N. et al, (2016), Physiol Rep, 4

Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man.

Hazlehurst JM. et al, (2016), J Clin Endocrinol Metab, 101, 103 - 113

Load More